Clinical Trial Update: BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies

View source ↗

Summary

Non-interventional (observational) studies of rivaroxaban (Xarelto) in atrial fibrillation have completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Atrial Fibrillation | Status: COMPLETED